Sensorion (FR0012596468 – ALSEN) announced that an independent Data Monitoring Committee found no safety concerns in its SENS-501 gene therapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE